Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

South African Rheumatism and Arthritis Association 2024 updated guidelines for the management of rheumatoid arthritis.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2024
Same author

Methodological Issues with Head and Neck Cancer Prognostic Risk Prediction Models.

Community dental health·2023
Same author

Understanding SARS-CoV-2 Delta and Omicron variant transmission and vaccine impact in schools and child-care settings in Australia: a population-based study.

The Lancet regional health. Western Pacific·2023
Same author

Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection.

Pathology·2021
Same author

Point of care and intensive care lung ultrasound: A reference guide for practitioners during COVID-19.

Radiography (London, England : 1995)·2020
Same author

Functional Outcomes and Urological Complications after Genital Gender Affirming Surgery with Urethral Lengthening in Transgender Men.

The Journal of urology·2020
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Focusing on plasma glycoprotein VI.

M Al-Tamimi1, J F Arthur, E Gardiner

  • 1Australian Centre for Blood Diseases, Alfred Medical Research & Education Precinct (AMREP), Monash University, Melbourne 3004, Australia. mohammad.al-tamimi@monash.edu

Thrombosis and Haemostasis
|January 26, 2012
PubMed
Summary
This summary is machine-generated.

New methods analyze glycoprotein VI (GPVI) in blood and the development of GPVI-based therapeutics. Understanding GPVI shedding and function offers new diagnostic and disease prevention strategies.

More Related Videos

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Related Experiment Videos

Last Updated: May 25, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Area of Science:

  • Biochemistry
  • Immunology
  • Hematology

Background:

  • Glycoprotein VI (GPVI) is a key platelet receptor mediating collagen-induced platelet activation.
  • GPVI plays a role in vascular injury, atherosclerosis, coagulopathy, rheumatoid arthritis, and tumor metastasis.
  • Soluble GPVI (sGPVI) in plasma offers potential diagnostic and therapeutic insights.

Purpose of the Study:

  • To review mechanisms of soluble GPVI generation from platelets.
  • To discuss the development of novel GPVI-based therapeutic compounds.
  • To explore the exploitation of GPVI for disease diagnosis and prevention.

Main Methods:

  • Analysis of platelet and plasma GPVI in experimental and clinical settings.
  • Development of dimeric soluble GPVI-Fc and anti-GPVI antibody-based therapeutics.
  • Investigation of GPVI ligand binding and shedding mechanisms.

Main Results:

  • Advancements in analyzing both platelet and plasma forms of GPVI.
  • Emergence of the first therapeutic compounds targeting GPVI.
  • Increased understanding of GPVI's pathophysiological roles.

Conclusions:

  • GPVI is a critical mediator in platelet activation and various diseases.
  • Soluble GPVI presents opportunities for diagnostic and preventative applications.
  • Targeting GPVI offers promising therapeutic avenues.